The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy.
D. Y. C. Heng
No relevant relationships to disclose
W. Xie
No relevant relationships to disclose
L. C. Harshman
Honoraria - Novartis
Research Funding - Genentech; Novartis
G. A. Bjarnason
No relevant relationships to disclose
U. N. Vaishampayan
No relevant relationships to disclose
J. Lebert
No relevant relationships to disclose
L. Wood
No relevant relationships to disclose
F. Donskov
No relevant relationships to disclose
M. Tan
No relevant relationships to disclose
S. Y. Rha
No relevant relationships to disclose
C. Wells
No relevant relationships to disclose
Y. Wang
No relevant relationships to disclose
C. K. Kollmannsberger
No relevant relationships to disclose
B. I. Rini
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
T. K. Choueiri
No relevant relationships to disclose